226 related articles for article (PubMed ID: 36570796)
21. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
22. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
23. Development and comparison of three
Hu G; Zhu W; Liu Y; Wang Y; Zhang Z; Zhu S; Duan W; Zhou P; Fu C; Li F; Huo L
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2634-2644. PubMed ID: 35347439
[TBL] [Abstract][Full Text] [Related]
24. Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors.
Zhang Y; Zhang D; An S; Liu Q; Liang C; Li J; Liu P; Wu C; Huang G; Wei W; Liu J
Research (Wash D C); 2023; 6():0077. PubMed ID: 36939440
[TBL] [Abstract][Full Text] [Related]
25. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody.
Yang Y; Wang C; Wang Y; Sun Y; Huang X; Huang M; Xu H; Fan H; Chen D; Zhao F
EJNMMI Res; 2021 Oct; 11(1):113. PubMed ID: 34718889
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
28. Development and characterization of CD54-targeted immunoPET imaging in solid tumors.
Wei W; Jiang D; Lee HJ; Li M; Kutyreff CJ; Engle JW; Liu J; Cai W
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2765-2775. PubMed ID: 32279097
[TBL] [Abstract][Full Text] [Related]
29. Site-specific
Dewulf J; Flieswasser T; Delahaye T; Vangestel C; Miranda A; de Haard H; Jacobs J; Smits E; Van den Wyngaert T; Elvas F
EJNMMI Radiopharm Chem; 2023 Apr; 8(1):8. PubMed ID: 37093350
[TBL] [Abstract][Full Text] [Related]
30. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.
Li ZB; Chen K; Chen X
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1100-8. PubMed ID: 18204838
[TBL] [Abstract][Full Text] [Related]
31. In vivo imaging of Aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer (68)Ga-NOTA-c(NGR).
Máté G; Kertész I; Enyedi KN; Mező G; Angyal J; Vasas N; Kis A; Szabó É; Emri M; Bíró T; Galuska L; Trencsényi G
Eur J Pharm Sci; 2015 Mar; 69():61-71. PubMed ID: 25592229
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and Evaluation of a Novel
Zhang H; Kanduluru AK; Desai P; Ahad A; Carlin S; Tandon N; Weber WA; Low PS
Bioconjug Chem; 2018 Apr; 29(4):1319-1326. PubMed ID: 29466853
[TBL] [Abstract][Full Text] [Related]
33. Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models.
Ehlerding EB; Lee HJ; Jiang D; Ferreira CA; Zahm CD; Huang P; Engle JW; McNeel DG; Cai W
Am J Cancer Res; 2019; 9(1):53-63. PubMed ID: 30755811
[TBL] [Abstract][Full Text] [Related]
34. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
35. Preparation and Evaluation of [
Dam JH; Langkjær N; Baun C; Olsen BB; Nielsen AY; Thisgaard H
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296411
[TBL] [Abstract][Full Text] [Related]
36. Annotating CD38 Expression in Multiple Myeloma with [
Wei W; Zhang D; Wang C; Zhang Y; An S; Chen Y; Huang G; Liu J
Mol Pharm; 2022 Oct; 19(10):3502-3510. PubMed ID: 34846151
[TBL] [Abstract][Full Text] [Related]
37. Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model.
Guo N; Lang L; Li W; Kiesewetter DO; Gao H; Niu G; Xie Q; Chen X
PLoS One; 2012; 7(5):e37506. PubMed ID: 22624041
[TBL] [Abstract][Full Text] [Related]
38. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
39. Targeting Infiltrating Myeloid Cells in Gastric Cancer Using a Pretargeted Imaging Strategy Based on Bio-Orthogonal Diels-Alder Click Chemistry and Comparison with
Zhang Y; Lin Q; Wang T; Shi D; Fu Z; Si Z; Xu Z; Cheng Y; Shi H; Cheng D
Mol Pharm; 2022 Jan; 19(1):246-257. PubMed ID: 34816721
[TBL] [Abstract][Full Text] [Related]
40. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
